So far, pharmaceutical and biomedical research firms have responded to Eroom’s law by cutting R&D or moving it to less expensive sites in Asia, shifting their focus to less prevalent diseases, and sourcing innovation externally. As a result, growth in biomedical R&D spending has declined from more than 9% annually in the early 2000’s to less than 3% today.